Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes

Cancer Microenvironment

Volumn 9, Issue 2-3, 2016, Pages 107-118

  Meseure, Didier ^a   Vacher, Sophie ^a   Drak Alsibai, Kinan ^a   Trassard, Martine ^a   Nicolas, André ^a   Leclere, Renaud ^a   Lerebours, Florence ^a   Guinebretiere, Jean Marc ^a   Marangoni, Elisabetta ^a   Lidereau, Rosette ^a   Bieche, Ivan ^a,b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Breast cancer subtypes; EMT; Toll like receptor 9; Tumor microenvironment signaling pathways

Indexed keywords

CD31 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TWIST RELATED PROTEIN 1; UVOMORULIN;

ADULT; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INVASIVE BREAST CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MIDDLE AGED; MOLECULAR DYNAMICS; MONONUCLEAR INFLAMMATORY CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

EID: 84978174551     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-016-0186-1     Document Type: Article

References (56)

1. Pal SK, Mortimer J (2009) Triple-negative breast cancer: novel therapies and new directions. Maturitas 63:269–74
2. Podo F, Buydens LM, Degani H et al (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209–29
3. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–67
4. Meseure D, Drak Alsibai K, Andre N (2014) Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron 3:95–115
5. Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A, Widschwendter M (2010) Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci 101:1059–66
6. Min C, Eddy SF, Sherr DH, Sonenshein GE (2008) NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104:733–744
7. Pratt MA, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C, Lau R, Niu MY (2009) The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 28:2710–2722
8. Akira S (2004) Toll receptor families: structure and function. Semin Immunol 16:1–2
9. Zeromski J, Mozer-Lisewska I, Kaczmarek M (2008) Significance of toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenviron 1:37–4
10. Fang C, Wei X, Wei Y (2015) Mitochondrial DNA in the regulation of innate immune responses. Protein Cell, Oct 23
11. De Nardo D (2015) Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine 74:181–9
12. Celhar T, Pereira-Lopes S, Thornhill SI, Lee HY, Dhillon MK, Poidinger M, Connolly JE3, Lim LH, Biswas SK, Fairhurst AM (2015) TLR7 and TLR9 ligands regulate antigen presentation by macrophages. Int Immunol Nov 13
13. Santoni M, Andrikou K, Sotte V, Bittoni A, Lanese A, Pellei C, Piva F, Conti A, Nabissi M, Santoni G, Cascinu S (2015) Toll like receptors and pancreatic diseases: from a pathogenetic mechanism to a therapeutic target. Cancer Treat Rev 41:569–76
14. Huhta H, Helminen O, Kauppila JH, Takala H, Metsikkö K, Lehenkari P, Saarnio J, Karttunen T (2015) Toll-like receptor 9 expression in the natural history of Barrett mucosa. Virchows Arch 467:9–18
15. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC (2009) Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 34:461–472
16. Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS (2008) Toll-like receptor 9 mediates CpG oligonucleotide induced cellular invasion. Mol Cancer Res 6:1534–1543
17. Bieche I, Onody P, Laurendeau I et al (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45:1148–1156
18. Alibek K, Kakpenova A, Mussabekova A, Sypabekova M, Karatayeva N (2013) Role of viruses in the development of breast cancer. Infect Agent Cancer 8:32–41
19. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989–98
20. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14:R11
21. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R (2001) Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20:8109–15
22. Bieche I, Noguès C, Lidereau R (1999) Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 18:5232–5238
23. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36
24. Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R (2003) Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106:758–65
25. Meseure D, Vacher S, Drak Alsibai K et al (2012) Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: a candidate biomarker to predict EGFR inhibitor effectiveness. Int J Cancer 131:1009–10
26. Damiano V, Caputo R, Bianco R, D’Armiento F (2006) Novel toll-like receptor 9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 12:577–583
27. Tuomela J, Sandholm J, Kaakinen M, Patel A, Kauppila JH, Ilvesaro J et al (2013) DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells. Breast Cancer Res Treat 142:477–87
28. Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang JJ, Kamimura D, Ogura H, Hirano T, Murakami M (2014) Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74:8–14
29. Rich AM, Hussaini HM, Parachuru VP, Seymour GJ (2014) Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol 5:464–465
30. Suwarti S, Yamazaki T, Svetlana C, Hanagata N (2013) Recognition of CpG oligodeoxynucleotides by human toll-like receptor 9 and subsequent cytokine induction. Biochem Biophys Res Commun 430:1234–924
31. Staudt L (2010) Oncogenic activation of NF-kB. Cold Spring Harb Perspect Biol 2:a000109
32. Sato Y, Goto Y, Narita N, Hoon D (2009) Cancer cells expressing Toll-like Receptors and the tumor microenvironment. Cancer Microenviron 2:205–214
33. Ridnour L, Cheng R, Switzer C et al (2013) Molecular pathways: toll-like receptors in the tumor microenvironment—poor prognosis or New therapeutic opportunity. Clin Cancer Res 6:1340–46
34. Fabbri M, Paone A, Calore F et al (2012) MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 31:109–31
35. Leng L, Jiang T, Zhang Y (2012) TLR9 expression is associated with prognosis in patients with glioblastoma multiforme. J Clin Neurosci 19:75–80
36. Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Increased toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology 59:643–9
37. Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS et al (2011) Absent toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res 30:84–90
38. Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP et al (2011) Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun 3:631–8
39. Väisänen MR, Jukkola-Vuorinen A, Vuopala KS, Selander KS, Vaarala MH (2013) Expression of toll-like receptor-9 is associated with poor progression-free survival in prostate cancer. Oncol Lett 5:1659–63
40. Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K et al (2010) TLR9 expressionin glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 10:415
41. Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P, Harris KW, Graves D, Auvinen PK, Soini Y, Jukkola-Vuorinen A, Selander KS (2012) Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat 135:481–93
42. Sandholm J, Selander KS (2014) Toll-like receptor 9 in breast carcinoma. Front Immunol 5:330–342
43. Mella M, Kauppila JH, Karihtala P, Lehenkari P, Jukkola-Vuorinen A, Soini Y, Auvinen P, Vaarala MH, Ronkainen H, Kauppila S, Haapasaari KM, Vuopala KS, Selander KS (2015) Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. Onco Immunol 4(6), e1002726, eCollection 2015
44. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809
45. Seyung S, Nolan G, Yanyuan W, Jaydutt V (2014) STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol 44:403–411
46. Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H (2014) TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res 74:5218–28
47. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44(þ)CD24(−) stem cell-like breast cancer cells in human tumors. J Clin Invest 121:2723–35
48. Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D’Apuzzo M, Forman S, Kortylewski M (2015) TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res 21:3771–82
49. Bayik D, Gursel I, Klinman DM (2016) Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. Pharmacol Res 105:216–25
50. Nelson MH, Bowers JS, Bailey SR, Diven MA, Fugle CW, Kaiser AD, Wrzesinski C, Liu B, Restifo NP, Paulos CM (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6. doi:10.1186/s40425-016-0110-8
51. Kortylewski M, Kuo Y (2014) Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity. OncoImmunology 2, e27441
52. Bishop JL, Thaper D, Zoubeidi A (2014) The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers 6:829–859
53. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11–19
54. Ouédraogo ZG, Müller-Barthélémy M, Kemeny JL, Dedieu V, Biau J, Khalil T, Raoelfils LI, Granzotto A, Pereira B, Beaudoin C, Guissou IP, Berger M, Morel L, Chautard E, Verrelle P (2015) STAT3 serine 727 Phosphorylation: a relevant target to Radiosensitize human glioblastoma. Brain Pathol. doi:10.1111/bpa.12254
55. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N (2013) Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 73:4629–40
56. Manegold C, van Zandwijk N, Szczesna A et al (2012) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23:72–7